Orama Therapeutics

Orama was established to develop novel therapies for the treatment of ophthalmic diseases, such as Meibomian Gland Dysfunction .

Our lead product OT-270 cream contains a novel selective glucocorticoid receptor agonist in development for the treatment of Meibomian Gland Dysfunction (MGD).